POS1117 1-YEAR FOLLOW-UP OUTCOME OF DIFFERENT TREATMENT REGIMENS FOR LUPUS NEPHRITIS
Authors: J. Sun, G. Wang
Journal: Annals of the Rheumatic Diseases (2024)

<h3>Background:</h3> Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies and damage to multiple organ systems. Lupus nephritis (LN) is the organ most commonly affected in SLE, and it is also one of the target organs of severe damage. The current response rate of LN is not ideal, which affects the quality of life and long-term survival of patients. <h3>Objectives:</h3> By retrospectively collecting and follow-up data of LN patients in our hospital, the characteristics and efficacy differences of different treatment regimens were objectively analyzed and summarized, hoping to provide reference value for subsequent clinical research and practice. <h3>Methods:</h3> In this study, we collected the general demographic characteristics, clinical manifestations, renal pathological classification, immunological indicators, laboratory test results, treatment regimens and treatment status of patients diagnosed with LN who were hospitalized in our hospital from January 2018 to December 2021 and underwent renal biopsy and the follow-up time was more than 1 year. <h3>Results:</h3> A total of 162 patients diagnosed with LNG by pathological diagnosis of SLE and renal biopsy from January 2018 to December 2021 were found through the medical record system, and a total of 98 cases were finally included after excluding patients who had been followed up for less than 1 year, and were divided into 3 groups according to different treatment drugs: 53 patients in the traditional treatment group, 32 patients in the multi-target group, and 13 patients in the biologics group. The results of remission at 3 months showed that the complete response rate (34.4%) in the multi-target group was significantly higher than that in the traditional treatment group (22.6%) and the biologics group (23.1%), the complete response rate at 6 months was higher in the multi-target group (62.5%) than in the biologics group (61.5%), and higher than that in the conventional treatment group (58.5%), and the complete response rate at 12 months in the biologics group (69.2%) was higher than that in the multi-target group (53.1%) and the conventional treatment group (47.2%). The results of proteinuria reduction in different treatment groups showed that the proteinuria was reduced by &gt;50% at 6 months of follow-up, 25 out of 32 patients (78.1%) in the multi-target group, 31 out of 53 patients (58.5%) in the traditional treatment group, and 9 out of 13 patients (69.2%) in the biologics group. Among the 32 patients in the multi-target group, 15 patients had no remission after receiving conventional therapy, and after switching to multi-target therapy, 26.7% of patients achieved complete remission at 6 months of treatment and 53.3% of patients achieved complete remission at 12 months of treatment. Two patients in the traditional treatment group reached ESRD, and the renal survival rate was 96.2%, and no one in the multi-target group and the biologics group reached ESRD. The survival rate of kidneys was 100%. <h3>Conclusion:</h3> 1.1-year treatment observation of LN patients: the 6-month complete response rate of the traditional treatment group and the multi-target group reached a peak, and the 12-month complete response rate of the biologics group was still further improved. 2.More patients in the multi-target group achieved the goal of induced remission therapy with a 50% reduction in proteinuria within 6 months. 3.Multi-targeted therapy as a salvage treatment has improved the response rate in patients with refractory LN. 4.The multi-target group and the biologics group can maintain the stability of renal function. Two patients in the traditional treatment group entered ESRD. <h3>REFERENCES:</h3> <b>NIL.</b> <h3>Acknowledgements:</h3> <b>NIL.</b> <h3>Disclosure of Interests:</h3> <b>None declared.</b>